CN110662538A - 甲酰肽受体2/脂氧素a4受体(fpr2/alx)激动剂用于治疗心力衰竭的新用途 - Google Patents

甲酰肽受体2/脂氧素a4受体(fpr2/alx)激动剂用于治疗心力衰竭的新用途 Download PDF

Info

Publication number
CN110662538A
CN110662538A CN201880033663.XA CN201880033663A CN110662538A CN 110662538 A CN110662538 A CN 110662538A CN 201880033663 A CN201880033663 A CN 201880033663A CN 110662538 A CN110662538 A CN 110662538A
Authority
CN
China
Prior art keywords
compound
heart failure
treatment
administration
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880033663.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·奥斯特罗夫斯基
R·加西亚
N·R·武尔茨
N·L·卡森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62567841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110662538(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN110662538A publication Critical patent/CN110662538A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880033663.XA 2017-05-22 2018-05-22 甲酰肽受体2/脂氧素a4受体(fpr2/alx)激动剂用于治疗心力衰竭的新用途 Pending CN110662538A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762509489P 2017-05-22 2017-05-22
US62/509,489 2017-05-22
PCT/US2018/033783 WO2018217684A1 (en) 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure

Publications (1)

Publication Number Publication Date
CN110662538A true CN110662538A (zh) 2020-01-07

Family

ID=62567841

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880033663.XA Pending CN110662538A (zh) 2017-05-22 2018-05-22 甲酰肽受体2/脂氧素a4受体(fpr2/alx)激动剂用于治疗心力衰竭的新用途

Country Status (15)

Country Link
US (1) US20200069644A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630097A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020520948A (cg-RX-API-DMAC7.html)
KR (1) KR20200006595A (cg-RX-API-DMAC7.html)
CN (1) CN110662538A (cg-RX-API-DMAC7.html)
AU (1) AU2018273382A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019024185A2 (cg-RX-API-DMAC7.html)
CA (1) CA3064291A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003325A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019013015A2 (cg-RX-API-DMAC7.html)
EA (1) EA201992704A1 (cg-RX-API-DMAC7.html)
IL (1) IL270749A (cg-RX-API-DMAC7.html)
MX (1) MX2019013926A (cg-RX-API-DMAC7.html)
PE (1) PE20200402A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018217684A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116390913A (zh) * 2020-10-09 2023-07-04 百时美施贵宝公司 氨基咪唑fpr2激动剂
CN117503932A (zh) * 2022-07-30 2024-02-06 中国医学科学院阜外医院 Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
EP4178946A1 (en) 2020-07-09 2023-05-17 Bristol-Myers Squibb Company Oxopyrrolidine fpr2 agonists
ES2986512T3 (es) 2020-07-09 2024-11-11 Bristol Myers Squibb Co Agonistas del receptor 2 del péptido formil pirazolona
WO2022035923A1 (en) 2020-08-12 2022-02-17 Bristol-Myers Squibb Company Oxopyrrolidine urea fpr2 agonists
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150106492A (ko) * 2014-03-11 2015-09-22 포항공과대학교 산학협력단 Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물
CN105814019A (zh) * 2013-11-28 2016-07-27 杏林制药株式会社 脲衍生物、或其药理学上所容许的盐

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536187A (ja) * 2002-04-03 2005-12-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト N−ホルミルペプチド受容体様1(fprl1)に関連する疾患の診断および治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105814019A (zh) * 2013-11-28 2016-07-27 杏林制药株式会社 脲衍生物、或其药理学上所容许的盐
KR20150106492A (ko) * 2014-03-11 2015-09-22 포항공과대학교 산학협력단 Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SOON CHUL HEO等: "Formyl Peptide Receptor 2 Is Involved in Cardiac Repair After Myocardial Infarction Through Mobilization of Circulating Angiogenic Cells", 《STEM CELLS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116390913A (zh) * 2020-10-09 2023-07-04 百时美施贵宝公司 氨基咪唑fpr2激动剂
CN117503932A (zh) * 2022-07-30 2024-02-06 中国医学科学院阜外医院 Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途

Also Published As

Publication number Publication date
AU2018273382A1 (en) 2020-01-16
IL270749A (en) 2020-01-30
EP3630097A1 (en) 2020-04-08
CL2019003325A1 (es) 2020-04-17
CO2019013015A2 (es) 2020-01-17
BR112019024185A2 (pt) 2020-06-02
MX2019013926A (es) 2020-01-20
WO2018217684A1 (en) 2018-11-29
KR20200006595A (ko) 2020-01-20
CA3064291A1 (en) 2018-11-29
US20200069644A1 (en) 2020-03-05
PE20200402A1 (es) 2020-02-26
JP2020520948A (ja) 2020-07-16
EA201992704A1 (ru) 2020-03-19

Similar Documents

Publication Publication Date Title
US20200069644A1 (en) Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure
AU2024200693B2 (en) Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
Wu et al. Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats
JP2018016647A (ja) 新規方法
JP2020526483A (ja) 心筋節活性化剤で心不全を治療する方法
US20080032933A1 (en) Type V Phosphodiesterase Inhibitors and Natriuretic Polypeptides
JP2022523645A (ja) ミトコンドリアミオパチーの処置におけるPPARδアゴニストの使用
AU2022299103B2 (en) Methods of using aldosterone synthase inhibitors
US20180325869A1 (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease
US12253531B2 (en) Diagnostic or predictor of relapsing remitting multiple sclerosis
CN118340787A (zh) 药物
US20250152671A1 (en) Medical composition for treating patients exhibiting cardiac decompensation
TW200848012A (en) Combination of metformin R-(+)lipoate and antihypertensive agents for the treatment of diabetic hyperglycemia and diabetic complications
JP6688503B2 (ja) 医薬用組成物
US20130210861A1 (en) Methods and compositions for managing cardiovascular disease associated with chronic kidney disease
TW201904584A (zh) 減少或預防第ii型糖尿病患者中心血管事件之方法
US12419863B2 (en) Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
CN103203009B (zh) 一种五肽的部分代谢物用于制备抗心肌缺血产品的新用途
Guidat et al. Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases
US20230381190A1 (en) Methods and Treatment for Complex Lymphatic Malformations
WO2023200738A1 (en) Combination treatment of dilated cardiomyopathy comprising a tyrosine kinase inhibitor and a statin
WO2025245334A1 (en) Compounds that inhibit the interaction between tristetraprolin and cnot1 and methods of use
WO2023229605A1 (en) Methods and treatment for complex lymphatic malformations
CN120957749A (zh) 一种sglt2抑制剂与薄荷醇的组合及其治疗心脏疾病的用途
EA042615B1 (ru) Способы лечения синдрома альпорта и улучшения функции почек с использованием бардоксолон-метила

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200107

WD01 Invention patent application deemed withdrawn after publication